
ImageneBio, Inc. (NASDAQ:IMA – Free Report) – Stock analysts at HC Wainwright issued their FY2026 EPS estimates for ImageneBio in a research note issued on Friday, November 13th. HC Wainwright analyst A. He anticipates that the company will post earnings per share of ($3.55) for the year. HC Wainwright currently has a “Strong-Buy” rating on the stock. The consensus estimate for ImageneBio’s current full-year earnings is ($3.47) per share. HC Wainwright also issued estimates for ImageneBio’s Q4 2026 earnings at ($1.07) EPS, Q1 2027 earnings at ($1.19) EPS, Q2 2027 earnings at ($1.34) EPS, Q3 2027 earnings at ($1.51) EPS, Q4 2027 earnings at ($1.69) EPS, FY2027 earnings at ($5.73) EPS, FY2028 earnings at ($5.35) EPS, FY2029 earnings at ($5.03) EPS and FY2030 earnings at ($4.95) EPS.
Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of ImageneBio in a report on Friday, September 25th. One analyst has rated the stock with a Strong Buy rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $28.00.
View Our Latest Analysis on IMA
ImageneBio Stock Performance
IMA opened at $3.20 on Tuesday. The stock has a market capitalization of $36.32 million, a price-to-earnings ratio of -0.70 and a beta of 0.83. The company has a fifty day moving average of $4.36 and a 200 day moving average of $5.47. ImageneBio has a fifty-two week low of $3.13 and a fifty-two week high of $8.25.
ImageneBio (NASDAQ:IMA – Get Free Report) last released its earnings results on Monday, November 9th. The company reported ($0.91) EPS for the quarter, missing the consensus estimate of ($0.83) by ($0.08).
Hedge Funds Weigh In On ImageneBio
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in IMA. Rangeley Capital LLC grew its holdings in ImageneBio by 78.6% during the 1st quarter. Rangeley Capital LLC now owns 32,590 shares of the company’s stock valued at $163,000 after buying an additional 14,346 shares in the last quarter. Renaissance Technologies LLC increased its stake in ImageneBio by 23.6% in the 1st quarter. Renaissance Technologies LLC now owns 81,696 shares of the company’s stock worth $408,000 after acquiring an additional 15,600 shares during the last quarter. Hsbc Holdings PLC purchased a new stake in shares of ImageneBio during the 2nd quarter worth approximately $208,000. Stonepine Capital Management LLC purchased a new stake in shares of ImageneBio during the 2nd quarter worth approximately $539,044,000. Finally, BlackRock Inc. purchased a new stake in shares of ImageneBio during the 2nd quarter worth approximately $797,000. 75.00% of the stock is owned by institutional investors.
Recent ImageneBio Headlines
These are some of the IMA headlines that stood out recently:
- Positive Sentiment: A recent report says ImageneBio’s third-quarter loss narrowed as its clinical trials advanced, offering a favorable update on financial performance and pipeline progress. ImageneBio stock: Q3 loss narrows as clinical trials advance
- Positive Sentiment: HC Wainwright maintained a Strong-Buy rating, a supportive analyst view, while issuing earnings estimates across 2026–2030. ImageneBio analyst coverage
- Negative Sentiment: The estimates underscore substantial ongoing losses: HC Wainwright forecasts a loss of $3.55 per share in FY2026 and $5.73 in FY2027, versus the cited current-year consensus loss of $3.47. Its quarterly estimates also project losses increasing through 2027, which could weigh on sentiment about funding needs and the path to profitability.
About ImageneBio
ImageneBio, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for immune-mediated and inflammatory diseases. Its research and development pipeline includes investigational medicines at various stages of clinical development; the company does not yet have marketed products. Key programs include IMG-007, an investigational antibody targeting OX40 being studied for atopic dermatitis and other inflammatory conditions, and IMG-004, an oral investigational BTK inhibitor for immune-mediated diseases.
Further Reading
- Five stocks we like better than ImageneBio
- Microsoft’s Outage Barely Moved Its Stock, But a Bigger Risk May Be Building
- MongoDB’s Biggest Advantage May Be GitLab’s Biggest Weakness
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
Receive News & Ratings for ImageneBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImageneBio and related companies with MarketBeat.com's FREE daily email newsletter.
